GSK (LON:GSK – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Jefferies Financial Group in a report released on Thursday, Digital Look reports. They presently have a GBX 2,100 ($26.64) price objective on the stock. Jefferies Financial Group’s price objective points to a potential upside of 38.34% from the company’s current price.
A number of other research analysts also recently issued reports on GSK. Shore Capital restated a “buy” rating on shares of GSK in a research note on Wednesday, June 12th. Citigroup reaffirmed a “buy” rating and set a GBX 2,100 ($26.64) price target on shares of GSK in a research report on Monday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 1,950 ($24.74) price target on shares of GSK in a research note on Tuesday, June 18th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Tuesday, June 18th. Finally, Barclays reiterated an “equal weight” rating and set a GBX 1,725 ($21.88) target price on shares of GSK in a research report on Tuesday, May 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,791.25 ($22.72).
View Our Latest Research Report on GSK
GSK Price Performance
Insider Activity at GSK
In other news, insider Wendy Becker purchased 446 shares of the business’s stock in a transaction on Thursday, June 20th. The stock was purchased at an average cost of GBX 1,614 ($20.47) per share, with a total value of £7,198.44 ($9,131.60). 1.60% of the stock is owned by corporate insiders.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Further Reading
- Five stocks we like better than GSK
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Why Paychex Stock’s Dip is the Best Opportunity in Today’s Cycle
- 5 discounted opportunities for dividend growth investors
- Any Pullback in Tech May Signal a Rotation into These 3 Sectors
- How to Capture the Benefits of Dividend Increases
- 3 Stocks to Watch: Oracle, Casey’s, FedEx Signal Big Gains
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.